MONTPELLIER, France–(BUSINESS WIRE)– #fda–Womed®, the uterine health company developing innovative intrauterine treatments to free women from uterine pathologies, today announced that the Food and Drug Administration approved the PreMarket Approval (PMA) application of the Womed Leaf® for adult women undergoing hysteroscopic surgery for symptomatic moderate to severe intrauterine adhesions, also referred to as Asherman syndrome. Womed Leaf® is the first medical device to be approved for sale in the